AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 16, 2021
29864_dirs_2021-02-16_5b051ed8-74c1-4482-8c1d-9da8e25bc713.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-11
Reporting Person: Silva Paul M (SVP & Chief Accounting Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-11 | Common Stock | S | 1288 | $210.45 | Disposed | 24073 | Direct |
| 2021-02-11 | Common Stock | S | 210 | $211.32 | Disposed | 23863 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 169 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.45 (range $209.91 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.32 (range $211.10 to $211.50).